Madison Vaccines Incorporated (MVI) announced today it will present data at the Society for Immunotherapy of Cancer’s Annual Meeting on Nov. 11 in National Harbor, Md., that has “promise” to stimulate an immune response in patients with advanced prostate cancer.

“Using PD-1 inhibitors to make cancer cells vulnerable to the immune system is impressive science; however, it has not been available in the fight against prostate cancer until now,” MVI President Richard Lesniewski said in a statement. “Although these are very early findings, we at MVI are encouraged by the positive trend we are seeing here.”

According to a release, the research shows the combination of a PD-1 inhibitor with its MVI-816 vaccine is safe and does stimulate an immune response in patients with advanced prostate cancer.

The clinical trial is being conducted by Dr. Douglas McNeel at the University of Wisconsin.